Traws Pharma (ONTX) Stock Forecast, Price Target & Predictions
ONTX Stock Forecast
Traws Pharma stock forecast is as follows: a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
ONTX Analyst Ratings
According to 2 Wall Street analysts, Traws Pharma's rating consensus is 'Buy'. The analyst rating breakdown for ONTX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Apr 21, 2023 | H.C. Wainwright | - | Buy | Upgrade |
| May 18, 2021 | Guggenheim | - | Buy | Initialise |
Traws Pharma's last stock rating was published by H.C. Wainwright on Apr 21, 2023. The company Upgrade its ONTX rating from "null" to "Buy".
Traws Pharma Financial Forecast
Traws Pharma Revenue Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | $56.00K | $56.00K | - | - |
| Avg Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.25K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K |
| High Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.25K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K |
| Low Forecast | $2.72M | $60.00K | $60.00K | $60.00K | $65.33K | $69.25K | $69.25K | $79.00K | $80.00K | $73.67K | $73.00K |
| # Analysts | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - |
| Surprise % | - | - | - | - | - | - | - | 0.71% | 0.70% | - | - |
Traws Pharma's average Quarter revenue forecast for Jul 23 based on 1 analysts is $69.25K, with a low forecast of $69.25K, and a high forecast of $69.25K. ONTX's average Quarter revenue forecast represents a 23.66% increase compared to the company's last Quarter revenue of $56.00K (Mar 23).
Traws Pharma EBITDA Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - |
| EBITDA | - | - | - | - | - | - | - | $-6.13M | $-5.73M | - | - |
| Avg Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.25K | $-69.25K | $-79.00K | $-80.00K | $-4.23M | $-73.00K |
| High Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.25K | $-69.25K | $-79.00K | $-80.00K | $-3.39M | $-73.00K |
| Low Forecast | $-2.72M | $-60.00K | $-60.00K | $-60.00K | $-65.33K | $-69.25K | $-69.25K | $-79.00K | $-80.00K | $-5.08M | $-73.00K |
| Surprise % | - | - | - | - | - | - | - | 77.65% | 71.67% | - | - |
undefined analysts predict ONTX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Traws Pharma's previous annual EBITDA (undefined) of $NaN.
Traws Pharma Net Income Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - |
| Net Income | - | - | - | - | - | - | - | $-5.41M | $-5.00M | - | - |
| Avg Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-4.24M | $-4.16M |
| High Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-3.39M | $-4.16M |
| Low Forecast | $-5.16M | $-5.58M | $-5.26M | $-4.95M | $-5.33M | $-6.10M | $-6.58M | $-6.26M | $-5.84M | $-5.08M | $-4.16M |
| Surprise % | - | - | - | - | - | - | - | 0.86% | 0.86% | - | - |
Traws Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. ONTX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Traws Pharma SG&A Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - |
| SG&A | - | - | - | - | - | - | - | $2.11M | $2.02M | - | - |
| Avg Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.20M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M |
| High Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.20M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M |
| Low Forecast | $86.60M | $1.91M | $1.91M | $1.91M | $2.08M | $2.20M | $2.20M | $2.52M | $2.55M | $2.35M | $2.32M |
| Surprise % | - | - | - | - | - | - | - | 0.84% | 0.79% | - | - |
Traws Pharma's average Quarter SG&A projection for Jul 23 is $2.20M, based on 1 Wall Street analysts, with a range of $2.20M to $2.20M. The forecast indicates a 4.34% rise compared to ONTX last annual SG&A of $2.11M (Mar 23).
Traws Pharma EPS Forecast
| Dec 24 | Oct 24 | Jul 24 | Mar 24 | Dec 23 | Oct 23 | Jul 23 | Mar 23 | Dec 22 | Oct 22 | Jul 22 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | - | - | - | 1 | 2 | 1 | 1 | 1 | - | - | - |
| EPS | - | - | - | - | - | - | - | $-0.26 | $-0.24 | - | - |
| Avg Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 |
| High Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 |
| Low Forecast | $-0.24 | $-0.27 | $-0.25 | $-0.23 | $-0.25 | $-0.29 | $-0.31 | $-0.30 | $-0.28 | $-0.21 | $-0.20 |
| Surprise % | - | - | - | - | - | - | - | 0.87% | 0.86% | - | - |
According to undefined Wall Street analysts, Traws Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to ONTX previous annual EPS of $NaN (undefined).
Traws Pharma Peer Comparison by Price Target
ONTX Forecast FAQ
Is Traws Pharma a good buy?
Yes, according to 2 Wall Street analysts, Traws Pharma (ONTX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of ONTX's total ratings.
What are Traws Pharma's analysts' financial forecasts?
ONTX's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2.9M (high $2.9M, low $2.9M), average EBITDA is $-2.9M (high $-2.9M, low $-2.9M), average net income is $-20.938M (high $-20.938M, low $-20.938M), average SG&A $92.33M (high $92.33M, low $92.33M), and average EPS is $-0.995 (high $-0.995, low $-0.995).
Did the ONTX's actual financial results beat the analysts' financial forecasts?
Based on Traws Pharma's last annual report (Dec 2023), the company's revenue was $226B, beating the average analysts forecast of $282.83K by 79905710.14%. Apple's EBITDA was $-20.298T, beating the average prediction of $-283K by 7176673060.49%. The company's net income was $-18.948T, beating the average estimation of $-24.27M by 78071429.39%. Apple's SG&A was $9.09T, beating the average forecast of $9M by 100993522.21%. Lastly, the company's EPS was $-0.9, missing the average prediction of $-1.153 by -21.97%. In terms of the last quarterly report (Mar 2023), Traws Pharma's revenue was $56K, missing the average analysts' forecast of $79K by -29.11%. The company's EBITDA was $-6.134M, beating the average prediction of $-79K by 7664.56%. Traws Pharma's net income was $-5.413M, missing the average estimation of $-6.26M by -13.54%. The company's SG&A was $2.11M, missing the average forecast of $2.52M by -15.99%. Lastly, the company's EPS was $-0.26, missing the average prediction of $-0.297 by -12.61%